1868 related articles for article (PubMed ID: 29040589)
1. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
[TBL] [Abstract][Full Text] [Related]
2. The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF.
Massin N; Abdennebi I; Porcu-Buisson G; Chevalier N; Descat E; Piétin-Vialle C; Goro S; Brussieux M; Pinto M; Pasquier M; Bry-Gauillard H
Hum Reprod; 2023 May; 38(5):927-937. PubMed ID: 36864699
[TBL] [Abstract][Full Text] [Related]
3. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
5. Does dual oocyte retrieval with continuous FSH administration increase the number of mature oocytes in low responders? An open-label randomized controlled trial.
Boudry L; Mateizel I; Wouters K; Papaleo E; Mackens S; De Vos M; Racca A; Adriaenssens T; Tournaye H; Blockeel C
Hum Reprod; 2024 Mar; 39(3):538-547. PubMed ID: 38199789
[TBL] [Abstract][Full Text] [Related]
6. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
7. Cumulative live birth rates in low-prognosis women.
Leijdekkers JA; Eijkemans MJC; van Tilborg TC; Oudshoorn SC; van Golde RJT; Hoek A; Lambalk CB; de Bruin JP; Fleischer K; Mochtar MH; Kuchenbecker WKH; Laven JSE; Mol BWJ; Torrance HL; Broekmans FJM;
Hum Reprod; 2019 Jun; 34(6):1030-1041. PubMed ID: 31125412
[TBL] [Abstract][Full Text] [Related]
8. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
[TBL] [Abstract][Full Text] [Related]
9. Serum progesterone is lower in ovarian stimulation with highly purified HMG compared to recombinant FSH owing to a different regulation of follicular steroidogenesis: a randomized controlled trial.
Bosch E; Alamá P; Romero JL; Marí M; Labarta E; Pellicer A
Hum Reprod; 2024 Feb; 39(2):393-402. PubMed ID: 38037188
[TBL] [Abstract][Full Text] [Related]
10. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
[TBL] [Abstract][Full Text] [Related]
11. Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients.
Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM; Humaidan P; Alviggi C
Hum Reprod; 2021 Jul; 36(8):2157-2169. PubMed ID: 34179973
[TBL] [Abstract][Full Text] [Related]
12. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
[TBL] [Abstract][Full Text] [Related]
13. The effect of polymorphisms in FSHR and FSHB genes on ovarian response: a prospective multicenter multinational study in Europe and Asia.
Polyzos NP; Neves AR; Drakopoulos P; Spits C; Alvaro Mercadal B; Garcia S; Ma PQM; Le LH; Ho MT; Mertens J; Stoop D; Tournaye H; Vuong NL
Hum Reprod; 2021 May; 36(6):1711-1721. PubMed ID: 33889959
[TBL] [Abstract][Full Text] [Related]
14. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study.
Blockeel C; Polyzos NP; Derksen L; De Brucker M; Vloeberghs V; van de Vijver A; De Vos M; Tournaye H
Hum Reprod; 2014 Jul; 29(7):1500-7. PubMed ID: 24813196
[TBL] [Abstract][Full Text] [Related]
15. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial.
Griesinger G; Blockeel C; Sukhikh GT; Patki A; Dhorepatil B; Yang DZ; Chen ZJ; Kahler E; Pexman-Fieth C; Tournaye H
Hum Reprod; 2018 Dec; 33(12):2212-2221. PubMed ID: 30304457
[TBL] [Abstract][Full Text] [Related]
16. Comparison of blastocyst euploidy rates following luteal versus follicular phase stimulation in a GnRH antagonist protocol: a prospective study with repeated ovarian stimulation cycles.
Martinez F; Clua E; Roca M; Garcia S; Polyzos NP
Hum Reprod; 2022 Nov; 37(12):2777-2786. PubMed ID: 36269092
[TBL] [Abstract][Full Text] [Related]
17. Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial.
Bosdou JK; Venetis CA; Dafopoulos K; Zepiridis L; Chatzimeletiou K; Anifandis G; Mitsoli A; Makedos A; Messinis IE; Tarlatzis BC; Kolibianakis EM
Hum Reprod; 2016 May; 31(5):977-85. PubMed ID: 26956551
[TBL] [Abstract][Full Text] [Related]
18. Comparison of early versus late initiation of GnRH antagonist co-treatment for controlled ovarian stimulation in IVF: a randomized controlled trial.
Hamdine O; Macklon NS; Eijkemans MJ; Laven JS; Cohlen BJ; Verhoeff A; van Dop PA; Bernardus RE; Lambalk CB; Oosterhuis GJ; Holleboom CA; van den Dool-Maasland GC; Verburg HJ; van der Heijden PF; Blankhart A; Fauser BC; Broekmans FJ;
Hum Reprod; 2013 Dec; 28(12):3227-35. PubMed ID: 24129613
[TBL] [Abstract][Full Text] [Related]
19. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.
van Tilborg TC; Torrance HL; Oudshoorn SC; Eijkemans MJC; Koks CAM; Verhoeve HR; Nap AW; Scheffer GJ; Manger AP; Schoot BC; Sluijmer AV; Verhoeff A; Groen H; Laven JSE; Mol BWJ; Broekmans FJM;
Hum Reprod; 2017 Dec; 32(12):2496-2505. PubMed ID: 29121326
[TBL] [Abstract][Full Text] [Related]
20. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
